Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639184 | 1.00 | DUT (0.33) | DUTTOP2A | |
| SCHEMBL22639340 | 1.00 | DUT (0.33) | DUTTOP2A | |
| SCHEMBL14255134 | 0.89 | DUT (0.31) | DUT | |
| SCHEMBL14255133 | 0.89 | DUT (0.31) | DUT | |
| SCHEMBL8068702 | 0.89 | DUT (0.31) | DUT | |
| SCHEMBL9632845 | 0.89 | DUT (0.31) | DUT | |
| SCHEMBL20225134 | 0.89 | DUT (0.31) | DUT | |
| SCHEMBL6857582 | 0.83 | CYP3A4 (0.33) | DUT | |
| SCHEMBL6271581 | 0.78 | — | — | |
| SCHEMBL1578986 | 0.77 | FUCA1 (0.41) | DUTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250303002-A1 | PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPY | San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation (US) | 2025-10-02 | — | — | US | disclosed |
| US-12329828-B2 | Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy | SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4404942-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-31 | — | — | EP | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| EP-4240849-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-09-13 | — | — | EP | disclosed |
| CN-116507724-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| US-20220088226-A1 | PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPY | SAN DIEGO STATE UNIVERSITY FOUNDATION (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088226-A1 | PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPY | DNA2, SLC29A2, PCNA | DUT 14/4885TOP2A 47/4885 |
| US-12329828-B2 | Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy | DNA2, SLC29A2, PCNA | DUT 14/4885TOP2A 47/4885 |
| US-20250303002-A1 | PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPY | DNA2, SLC29A2, PCNA | DUT 14/4885TOP2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.